Shortly after acquiring Elektrofi to beef up its subcutaneous drug-delivery offerings, Halozyme Therapeutics has struck another deal to purchase Surf Bio. To take over Surf, Halozyme is paying $300 million upfront, subject to customary purchase price adjustments, and up to $100 million in development and regulatory milestones. Halozyme announced the deal as it raised its 2026 total revenue guidance by 19% at the midpoint to a range between $1.71 billion to $1.81 billion. That’s compared with an estimated $1.385 billion to $1.4 billion for 2025.
Read the full article: Halozyme Catches M&A Wave to Snap up Surf Bio in Delivery Tech Deal Worth up to $400M //
Source: https://www.fiercepharma.com/pharma/halozyme-catches-ma-wave-snap-surf-bio-delivery-tech-deal-worth-400m